Australia Expands FLUAD Vaccine Access to Ages 50 and Over

Australia has expanded access to CSL Seqirus' influenza vaccine, FLUAD. The approval for the vaccine has been extended to individuals aged 50 and over.

Health experts indicate that this expansion addresses the increased risk of serious flu complications in individuals beginning in midlife.